Selling an Infusion Therapy Business in 2026: Multiples, Named Buyers, and the Operator Playbook

If you operate an infusion therapy business in 2026 — whether that is a single ambulatory infusion center, a regional home-infusion pharmacy, or a multi-state specialty infusion platform — the M&A market is active and capital-deep. Option Care Health is consolidating, Optum Infusion Pharmacies (UnitedHealth) is the strategic giant, BrightSpring (Amerita) went public in January 2024, KabaFusion sold to Court Square Capital in 2023 in a $850M+ disclosed transaction, and Soleo Health, NaviCare, and CSI Pharmacy continue to roll up regional infusion businesses.

What the asset is worth depends on three things: (1) the payer mix and named in-network commercial contract status, (2) accreditation and licensure footprint (ACHC, URAC, state board of pharmacy, multi-state), and (3) drug-access positioning — specifically whether you have limited-distribution-drug (LDD) access and named relationships with manufacturers/specialty wholesalers. This guide gives you real multiples ranges, the named buyers actually transacting, and the operator-level diligence buyers will run.

Named infusion therapy M&A transactions (2022-2025)

The transactions below are public or widely-disclosed deals. They show a deeply capitalized buyer pool and an active market:

The named buyer landscape

The most important thing a seller needs to know is who is actually buying infusion businesses right now, what they pay for, and what they will reject. The buyer pool falls into three buckets:

Public / strategic buyers

• Option Care Health (NASDAQ: OPCH, ~$4B revenue) — the largest US dedicated home/alternate-site infusion provider. Active tuck-in acquirer.
• Optum Infusion Pharmacies (UnitedHealth Group, OptumRx) — emerged from the 2014 Coram acquisition from CVS. Strategic giant, selective on M&A but writes big checks for the right asset.
• BrightSpring Health Services (NASDAQ: BTSG) — IPO’d January 2024. Parent of Amerita home-infusion. Active acquirer across its diversified home/specialty health services portfolio.

PE-backed specialty infusion platforms

• KabaFusion (Court Square Capital, acquired 2023, $850M+ disclosed) — multi-state specialty/home infusion platform.
• Soleo Health (Court Square Capital) — specialty pharmacy / specialty infusion platform.
• CSI Pharmacy (Linden Capital) — specialty pharmacy and home-infusion.
• NaviCare Infusion — private, active in the AIC and home-infusion segments.
• Premier Specialty Pharmacy, BioPlus Specialty Pharmacy (Elevance), and several other PE-backed and strategic-backed specialty infusion platforms remain active acquirers.

Adjacent PE sponsors writing checks in this space

• Court Square Capital — KabaFusion + Soleo.
• Linden Capital — CSI Pharmacy + multiple other healthcare investments.
• H.I.G. Capital, Webster Equity Partners, Frazier Healthcare, Avista Healthcare Partners — multiple healthcare-services investments including infusion-adjacent businesses.

What each buyer will pay for vs. what they reject

• Will pay premium for: named commercial in-network status, multi-state licensure (state board of pharmacy), ACHC and URAC accreditation, LDD access and named manufacturer/wholesaler relationships, named referral relationships with hospital systems and specialty practices, audited financials, clean state-board compliance, modern pharmacy management system.
• Will compress or reject: heavy AIC Medicare Part B reimbursement concentration (J-code buy-and-bill margin compression risk), single-state licensure without a clear multi-state growth plan, no LDD access, open state-board pharmacy findings or DEA matters, single-payer concentration above 25%, single-referrer concentration above 20%, unaudited financials.

The operator-level KPI playbook buyers will diligence

Drug mix and reimbursement

• Top therapeutic categories: IVIG, biologics (Remicade, Entyvio, Ocrevus, etc.), antimicrobials/OPAT, TPN, hydration, chemotherapy, hemophilia. Each has different margin profile and growth dynamics.
• Average reimbursement per visit: Track by therapy type. IVIG and biologics have the highest per-visit revenue (often $5,000-$25,000+); hydration/antimicrobials have lower revenue per visit ($300-$1,500).
• LDD access: Number of limited-distribution drugs the operation has access to; named relationships with manufacturers and specialty wholesalers (AmerisourceBergen, Cardinal Health, McKesson Specialty).
• Drug cost ratio: Track drug cost as % of revenue; buy-and-bill margin compression on Medicare Part B is a real risk.

Payer mix

• Commercial payer percentage: 60%+ commercial is the platform benchmark.
• Medicare Part B vs. Part D split: Part B (buy-and-bill, AIC-typical) vs. Part D (specialty pharmacy distribution) has different margin profile and growth dynamics.
• In-network status: Anthem/Elevance, UnitedHealthcare, Aetna, Cigna, BCBS by state — named in-network status is non-negotiable for premium multiples.
• Single-payer concentration: No single commercial payer over 25%.

Referral and client concentration

• Referral source diversification: Hospital systems, infectious-disease practices, GI practices, IVIG-prescribing neurologists, oncologists. No single referrer over 20% of revenue.
• Named relationships: Document the top-20 referrers, average referrals/month, and tenure of the relationship.
• Account manager / clinical liaison structure: Documented model and territory.

Accreditation, licensure, and compliance

• Accreditation: ACHC, URAC, CMS DMEPOS as applicable. Verify all current with no findings.
• State board of pharmacy: Licensed in every state of operation. Document multi-state licensure footprint.
• DEA registration: Current and clean.
• USP 797 / 800 compliance: Cleanroom certifications, environmental monitoring documentation.
• Pharmacist-to-technician ratio: State-specific requirements.

Clinical operations

• Per-pharmacy throughput: Compounded sterile preparations per day, dispensed prescriptions per day.
• Patient safety incidents: Track all incidents and root-cause analyses.
• Nursing model: W-2 vs. 1099 vs. agency; named partner agencies if applicable.
• Patient adherence: Refill rates, missed-dose tracking, persistence by therapy type.

RCM and financial controls

• Days in AR: <45 days is healthy.
• Denial rate: <8% first-pass.
• Prior-authorization automation: Documented PA workflow, average PA turnaround.
• Inventory turns: Specialty drug inventory turns by SKU; aged inventory disclosure.

Dangers and traps in infusion therapy M&A

1. Medicare Part B buy-and-bill margin compression

If a large share of revenue is Medicare Part B J-code buy-and-bill (AIC-typical), buyers will model in continued reimbursement risk (sequestration, biosimilar substitution, ASP+6% pressure). Diversified commercial payer mix is the multiple-builder.

2. Single-state licensure without a growth path

Platform buyers want multi-state operations or a clear path to it. Single-state licensure without documented expansion plans gets a single-state multiple.

3. LDD access as a moat (or lack of it)

Limited-distribution drugs are a defensible source of margin. Without named LDD access and manufacturer relationships, you are competing on price for commodity drugs. Document every LDD relationship.

4. State-board pharmacy findings and DEA matters

Any open or recent state-board pharmacy finding, DEA inspection issue, or USP 797/800 compliance gap is a real diligence concern. Resolve and document before going to market.

5. Referral concentration

Single hospital system or single specialty practice referrer above 20% of revenue is a churn-risk reserve. Diversify and document long-tenured relationships.

6. Nursing model exposure

If you rely heavily on 1099 or agency nursing without strong documentation, expect buyer-side questions on classification and compliance. W-2 or named-partner-agency models are cleaner.

7. Aged inventory and drug-cost ratio surprises

Specialty drug inventory turns slowly. Aged inventory disclosed late in diligence is a repricing event. Get ahead of it with clean inventory reporting.

8. Anti-kickback and Sunshine-Act compliance

Manufacturer/payer relationships, sales-rep comp models, and referral-source arrangements should all be reviewed by counsel. Anti-kickback exposure is a binary “walk” risk for some buyers.

Our POV on infusion therapy M&A in 2026

The honest read on the market: infusion is a deeply capitalized M&A space. The public strategics (Option Care, Optum, BrightSpring), the PE-backed specialty platforms (KabaFusion/Soleo via Court Square, CSI via Linden), and the regional consolidators have real capital and are buying selectively.

• If you are a single-site AIC, multiples are 5x-7x. Buyer pool is regional roll-ups and the larger platforms doing geographic tuck-ins. Focus on commercial payer mix and clean operations.
• If you are a small regional infusion group (3-10 sites or $2-5M EBITDA), you are the sweet spot for tuck-in M&A by the named platforms. Multiples 6x-9x. A real competitive process matters.
• If you are a mid-size home/specialty platform ($5-15M EBITDA), you are most leveraged. PE sponsors and the public strategics will pay 8x-11x. LDD access and multi-state licensure are differentiators.
• If you are a premium scale specialty platform (multi-state ACHC/URAC, named LDD access, in-network commercial contracts, $15M+ EBITDA), you are a strategic target. 11x-14x+ is achievable in a competitive process.

The right time to prepare is 12-18 months before going to market — clean up state-board compliance, document LDD relationships, diversify referrers and payers, and get audited financials in place. The buyer pool will pay for quality.

Preparing your infusion business for sale: 12-18 months out

1. Get multi-year audited financials. Plan for at least 2 years of audited or reviewed statements.
2. Run a compliance audit. Health-care counsel + a pharmacy compliance specialist should review state-board licensure, USP 797/800 compliance, DEA registration, anti-kickback exposure, and Sunshine-Act compliance. Resolve issues before going to market.
3. Document the LDD access map. List every limited-distribution drug, named manufacturer/wholesaler relationship, and contractual terms. This is the most defensible part of your business.
4. Diversify referral and payer concentration. Top referrer and top payer concentration management is high-leverage work pre-sale.
5. Confirm multi-state licensure footprint. Every state where you operate should have current licensure, no open findings.
6. Document accreditation cleanly. ACHC, URAC, CMS DMEPOS as applicable. No open findings, current surveys.
7. Build the clinical leadership bench. A real Director of Pharmacy and CMO that can stay through transition is a multiple-builder.
8. Document add-backs. Owner compensation above market, personal expenses, one-time items, transaction costs. Contemporaneous documentation only.
9. Run a competitive process. Option Care, Optum, BrightSpring, the PE-backed platforms (KabaFusion, Soleo, CSI, NaviCare), plus regional buyers — a real auction with multiple buyers in the room is worth 1-3 turns of EBITDA over a single-bidder negotiation.

The five pillars of how CT Acquisitions works

Frequently asked questions

What is the typical multiple for an infusion therapy business in 2026?

Single-site ambulatory infusion centers (AICs) typically sell at 5x-7x EBITDA. Small regional infusion groups go 6x-9x. Mid-size home/specialty infusion platforms ($5-15M EBITDA) go 8x-11x. Premium scale multi-state specialty platforms with ACHC/URAC accreditation, LDD access, and in-network commercial contracts go 11x-14x+.

Who are the active buyers of infusion therapy businesses right now?

Public/strategic: Option Care Health (NASDAQ: OPCH, ~$4B revenue), Optum Infusion Pharmacies (UnitedHealth Group), BrightSpring Health Services / Amerita (NASDAQ: BTSG, IPO Jan 2024). PE-backed specialty platforms: KabaFusion (Court Square Capital, ~$850M+ disclosed 2023), Soleo Health (Court Square), CSI Pharmacy (Linden Capital), NaviCare Infusion, Premier Specialty Pharmacy. PE sponsors with healthcare-services investments include H.I.G. Capital, Webster Equity Partners, Frazier Healthcare, Avista Healthcare Partners.

What hurts an infusion business’s valuation most?

Heavy Medicare Part B buy-and-bill concentration (ASP+6% margin compression risk), single-state licensure without a multi-state growth path, no LDD access, open state-board pharmacy findings or DEA matters, single-payer concentration above 25%, single-referrer concentration above 20%, anti-kickback or Sunshine-Act exposure, and unaudited financials.

What is LDD access and why does it matter?

LDD (limited-distribution drug) access means the manufacturer or specialty wholesaler has agreed to supply specific specialty drugs through your pharmacy in a restricted distribution network. LDD access is a real margin moat — without it, you compete on price for commodity drugs. Document every LDD relationship; it is the most defensible part of the business.

How long does it take to sell an infusion therapy business?

Once you go to market with a buyer-paid advisor, a typical process runs 6-9 months from initial outreach to closing, with the longer end driven by regulatory and compliance diligence. Add 12-18 months of preparation work before going to market.

Do I have to pay a broker fee?

No. CT Strategic Partners runs a buyer-paid M&A advisory model. The seller pays nothing. The buyer pays the success fee at closing as part of their acquisition cost. This is structurally different from a traditional business-broker engagement (which charges the seller 8-12% of deal value).

Are ambulatory infusion centers (AICs) and home-infusion pharmacies in the same M&A market?

They overlap but have distinct buyer dynamics. AICs are typically Medicare Part B buy-and-bill and lower multiples. Home/specialty infusion pharmacies are typically Part D / specialty distribution, higher multiples, with the named platform buyers (Option Care, Optum, BrightSpring, the PE-backed platforms) more active in home/specialty. Many sellers operate both, and the M&A story benefits from the diversified mix.

When should I start preparing if I plan to sell in 2027 or 2028?

12-18 months before going to market is the right window. That gives time to clean up financials, resolve any regulatory matters, diversify referral and payer concentration, document LDD relationships, confirm multi-state licensure, and build the clinical leadership bench. Starting 3-6 months out leaves significant value on the table.

Related research

• How to sell a home health agency
• How to sell a clinical laboratory
• How to sell an urgent care center
• How to sell a physical therapy practice
• How to sell a medical billing company
• How to sell a medical device manufacturing business
• Healthcare business valuation
• Which industries is PE buying most in 2026
• Private equity value creation
• Business broker alternative

About the Author

Christoph Totter is the founder of CT Acquisitions, a buy-side partner headquartered in Sheridan, Wyoming. We work directly with 76+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest home services consolidators that other intermediaries can’t access. The buyers pay us when a deal closes, not the seller. No retainer, no exclusivity, no contract until close. Connect on LinkedIn · Get in touch